ThromboGenics and BioInvent Ink Deal With Roche

Image via Wikipedia

BioInvent and ThromboGenics have entered into a license agreement with Roche for, TB-403, their novel mAb targeting Placental Growth Factor (PIGF) for the treatment of cancer. Under the terms of the agreement:
Roche will pay BioInvent and ThromboGenics an upfront payment of €50 million. In addition, BioInvent and ThromboGenics could potentially receive up to [...]